EFSD and Lilly Renew Commitment to Innovate Diabetes Research and Education

DÜSSELDORF, GERMANY and INDIANAPOLIS, US, 17 September 2019 – The European Foundation for the Study of Diabetes (EFSD) and Eli Lilly and Company (NYSE: LLY) signed a new three-year, more than €6 million commitment designed to innovate research and education, and drive new solutions for the benefit of people with diabetes. The new programme, which runs until 2022, will expand the scope of the current collaboration and builds on nearly two decades of partnership between Lilly and the European Association for the Study of Diabetes (EASD). The organisations announced the news at the 55th Annual Meeting of the EASD in Barcelona, Spain.

“EFSD is delighted to strengthen our already strong collaboration with Lilly to drive further innovation across all areas of diabetes research and education in Europe,” said Professor Stefano Del Prato, Chairman of EFSD. “Investments and collaboration with innovation at the heart represent true opportunities to not only deliver exciting science, but to actually make life better for people facing this chronic disease. We’re proud of the programmes, research and education stemming from our long-term collaboration with Lilly, and look forward to future successes.”

The renewed commitment, which runs 2020-2022, expands the range and depth of the collaboration, launched in 2017 to develop new, innovative solutions for people with diabetes in Europe and around the world.

At the end of 2019, EFSD and Lilly expect to launch a new programme, EXPAND (Exploring and Applying New Strategies in Diabetes), dedicated to translational research. Focussing on transforming currently available knowledge into useful measures for everyday clinical and public health practices, the programme seeks to facilitate the implementation of standards of care, address the barriers to
implementation, and identify across all levels of health care delivery how to improve quality of care and outcomes, including quality of life.

“Adding new programmes like EXPAND to the already rewarding collaboration with EFSD emphasises our shared intent to improve the well-being of people with diabetes and encourage the development of innovative solutions,” commented Robert Heine, MD, PhD, Distinguished Lilly Scholar.

“Lilly has been improving the lives of people with diabetes since 1923, and today’s announcement marks an important step into the future of diabetes care. Our continued collaboration with EFSD not only marks our commitment to expanding research and education in a time where more and more people are diagnosed with diabetes and related conditions, but it marks our constant pursuit of innovation to make life better”, added Dr Heine.

In addition to new programmes, the collaboration will continue to deliver successful existing programmes including the EFSD-Lilly European Diabetes Research Programme – which encompasses basic and clinical research – as well as the prestigious lecture, the Albert Renold Prize. Other initiatives extended under the agreement include two post-graduate courses for young physicians’ development, the EASD Scientists Training Course and the EASD Robert Turner Clinical Research Course, as well as the EFSD-Lilly Young Investigator Research Award Programme.

About EFSD
The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) in 2000 to provide funding in all areas of diabetes research across the entire European Region. The aims of EFSD are to encourage and support groundbreaking diabetes research and to promote the next generation of leading diabetes researchers. Since its inception, EFSD has committed over Euro 100 million to diabetes research in Europe by various funding means. More information about EFSD can be found at: www.europeandiabetesfoundation.org

About EASD
The European Association for the Study of Diabetes e.V. (EASD) is a membership based academic non-profit organisation with more than 4,000 members from over 110 countries. It was founded in 1965 and is based in Düsseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.
The EASD Annual Meeting is one of the largest diabetes related conferences in the world with more than 15,000 participants from over 130 countries. EASD is also an active player in postgraduate education, organising numerous courses each year both inside and outside Europe. Since 1972, EASD has trained over 30,000 health care professionals through postgraduate training courses and online education activities.

EASD is the publisher of *Diabetologia*, a major monthly international diabetes journal. For more information, please visit: [www.easd.org](http://www.easd.org).

**About Lilly Diabetes**
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit [www.lillydiabetes.com](http://www.lillydiabetes.com).

**About Eli Lilly and Company**
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at [lilly.com](http://lilly.com) and [lilly.com/newsroom](http://lilly.com/newsroom).